Elizabeth C. James

Portsmouth, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Electromagnetic fields from submarine power cables: A 35 Year synthesis of effects on aquatic biota.

Electromagnetic fields from submarine power cables: A 35 Year synthesis of effects on aquatic biota.

Journal: Marine environmental research

Published: October 16, 2025

Assessing a facilitated social network intervention for health outcomes in lonely and socially isolated people: the pragmatic, cluster-randomized PALS trial.

Assessing a facilitated social network intervention for health outcomes in lonely and socially isolated people: the pragmatic, cluster-randomized PALS trial.

Journal: Frontiers in public health

Published: September 08, 2025

Social network intervention for loneliness and social isolation in a community setting: the PALS cluster-RCT.

Social network intervention for loneliness and social isolation in a community setting: the PALS cluster-RCT.

Journal: Public health research (Southampton, England)

Published: March 08, 2025

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 17, 2022

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: February 24, 2022

Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.

Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.

Journal: The Cochrane database of systematic reviews

Published: February 21, 2022

Testing approaches to sharing trial results with participants: The Show RESPECT cluster randomised, factorial, mixed methods trial.

Testing approaches to sharing trial results with participants: The Show RESPECT cluster randomised, factorial, mixed methods trial.

Journal: PLoS medicine

Published: June 14, 2021

Examining the optimal factors that promote implementation and sustainability of a network intervention to alleviate loneliness in community contexts.

Examining the optimal factors that promote implementation and sustainability of a network intervention to alleviate loneliness in community contexts.

Journal: Health & social care in the community

Published: March 26, 2021

Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.

Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: July 20, 2020

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial.

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial.

Journal: Trials

Published: April 23, 2020

Progression-free survival in the ICON8 trial - Authors' reply.

Progression-free survival in the ICON8 trial - Authors' reply.

Journal: Lancet (London, England)

Published: March 06, 2020

Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.

Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.

Journal: The Lancet. Oncology

Published: February 18, 2020

Showing 1-12 of 20

Last Updated: 09/26/2026